{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:02:28Z","timestamp":1793898148917,"version":"4.8.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T00:00:00Z","timestamp":1752883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI158177"],"award-info":[{"award-number":["AI158177"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01198-7","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T18:07:30Z","timestamp":1752948450000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["A multi-antigen-based SARS-CoV-2 vaccine provides higher immune responses and protection against SARS-CoV-2 variants"],"prefix":"10.1038","volume":"10","author":[{"given":"Marwa","family":"Alhashimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekramy E.","family":"Sayedahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elkashif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhada K.","family":"Chothe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muralimanohara S. T.","family":"Murala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Gairola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Wakamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinay","family":"Gontu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhamani","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"LaBella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padmaja","family":"Jakka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meera Surendran","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth H.","family":"Nissly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh V.","family":"Kuchipudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh K.","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,19]]},"reference":[{"key":"1198_CR1","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/ije\/dyaa033","volume":"49","author":"NC Peeri","year":"2020","unstructured":"Peeri, N. C. et al. The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?. Int. J. Epidemiol. 49, 717\u2013726 (2020).","journal-title":"Int. J. Epidemiol."},{"key":"1198_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR3","unstructured":"COVID\u2014Coronavirus Statistics\u2014Worldometer. https:\/\/www.worldometers.info\/coronavirus\/ (2024)."},{"key":"1198_CR4","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"1198_CR5","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR6","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1016\/S0140-6736(20)31208-3","volume":"395","author":"FC Zhu","year":"2020","unstructured":"Zhu, F. C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845\u20131854 (2020).","journal-title":"Lancet"},{"key":"1198_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/imr.13088","volume":"310","author":"M Le Gars","year":"2022","unstructured":"Le Gars, M. et al. Immunogenicity and efficacy of Ad26.COV2.S: an adenoviral vector-based COVID-19 vaccine. Immunol. Rev. 310, 47\u201360 (2022).","journal-title":"Immunol. Rev."},{"key":"1198_CR8","doi-asserted-by":"publisher","first-page":"e2132540","DOI":"10.1001\/jamanetworkopen.2021.32540","volume":"4","author":"J Corchado-Garcia","year":"2021","unstructured":"Corchado-Garcia, J. et al. Analysis of the effectiveness of the Ad26.COV2.S adenoviral vector vaccine for preventing COVID-19. JAMA Netw. Open 4, e2132540 (2021).","journal-title":"JAMA Netw. Open"},{"key":"1198_CR9","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","volume":"396","author":"PM Folegatti","year":"2020","unstructured":"Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1\/2, single-blind, randomised controlled trial. Lancet 396, 467\u2013478 (2020).","journal-title":"Lancet"},{"key":"1198_CR10","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","volume":"384","author":"SA Madhi","year":"2021","unstructured":"Madhi, S. A. et al. Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant. N. Engl. J. Med. 384, 1885\u20131898 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR11","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S1473-3099(20)30942-7","volume":"21","author":"R Ella","year":"2021","unstructured":"Ella, R. et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect. Dis. 21, 637\u2013646 (2021).","journal-title":"Lancet Infect. Dis."},{"key":"1198_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1080\/14760584.2021.1991794","volume":"21","author":"D Mekonnen","year":"2022","unstructured":"Mekonnen, D., Mengist, H. M. & Jin, T. SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways. Expert Rev. Vaccines 21, 69\u201381 (2022).","journal-title":"Expert Rev. Vaccines"},{"key":"1198_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41577-021-00592-1","volume":"21","author":"JS Tregoning","year":"2021","unstructured":"Tregoning, J. S., Flight, K. E., Higham, S. L., Wang, Z. & Pierce, B. F. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat. Rev. Immunol. 21, 626\u2013636 (2021).","journal-title":"Nat. Rev. Immunol."},{"key":"1198_CR14","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/d41586-021-01505-x","volume":"594","author":"H Ledford","year":"2021","unstructured":"Ledford, H. Six months of COVID vaccines: what 1.7 billion doses have taught scientists. Nature 594, 164\u2013167 (2021).","journal-title":"Nature"},{"key":"1198_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/d41586-021-00727-3","volume":"592","author":"A Irwin","year":"2021","unstructured":"Irwin, A. What it will take to vaccinate the world against COVID-19. Nature 592, 176\u2013178 (2021).","journal-title":"Nature"},{"key":"1198_CR16","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41586-021-03944-y","volume":"599","author":"P Mlcochova","year":"2021","unstructured":"Mlcochova, P. et al. SARS-CoV-2 B.1.617.2 delta variant replication and immune evasion. Nature 599, 114\u2013119 (2021).","journal-title":"Nature"},{"key":"1198_CR17","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1002\/mco2.239","volume":"4","author":"D Ao","year":"2023","unstructured":"Ao, D., He, X., Hong, W. & Wei, X. The rapid rise of SARS-CoV-2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants. MedComm 4, e239 (2023).","journal-title":"MedComm"},{"key":"1198_CR18","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao, Y. et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 602, 657\u2013663 (2022).","journal-title":"Nature"},{"key":"1198_CR19","doi-asserted-by":"publisher","first-page":"e482","DOI":"10.1016\/S1473-3099(24)00415-8","volume":"24","author":"Y Kaku","year":"2024","unstructured":"Kaku, Y. et al. Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants. Lancet Infect. Dis. 24, e482\u2013e483 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1198_CR20","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.cmi.2021.10.005","volume":"28","author":"T Fiolet","year":"2022","unstructured":"Fiolet, T., Kherabi, Y., MacDonald, C. J., Ghosn, J. & Peiffer-Smadja, N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin. Microbiol. Infect. 28, 202\u2013221 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"1198_CR21","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/S1473-3099(22)00506-0","volume":"22","author":"K Hardt","year":"2022","unstructured":"Hardt, K. et al. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Infect. Dis. 22, 1703\u20131715 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1198_CR22","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","volume":"384","author":"J Sadoff","year":"2021","unstructured":"Sadoff, J. et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N. Engl. J. Med. 384, 2187\u20132201 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR24","doi-asserted-by":"publisher","first-page":"2939","DOI":"10.1016\/j.cell.2021.03.055","volume":"184","author":"W Dejnirattisai","year":"2021","unstructured":"Dejnirattisai, W. et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell 184, 2939\u20132954.e2939 (2021).","journal-title":"Cell"},{"key":"1198_CR25","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.cell.2021.02.037","volume":"184","author":"D Zhou","year":"2021","unstructured":"Zhou, D. et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. Cell 184, 2348\u20132361.e2346 (2021).","journal-title":"Cell"},{"key":"1198_CR26","doi-asserted-by":"publisher","unstructured":"Garcia-Beltran, W. F. et al. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv https:\/\/doi.org\/10.1101\/2021.02.14.21251704 (2021).","DOI":"10.1101\/2021.02.14.21251704"},{"key":"1198_CR27","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211 (2021).","journal-title":"Nat. Med."},{"key":"1198_CR28","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634 (2021).","journal-title":"Nature"},{"key":"1198_CR29","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/s41591-022-02092-8","volume":"29","author":"SM Scheaffer","year":"2023","unstructured":"Scheaffer, S. M. et al. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nat. Med. 29, 247\u2013257 (2023).","journal-title":"Nat. Med."},{"key":"1198_CR30","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/mt.2008.12","volume":"16","author":"N Singh","year":"2008","unstructured":"Singh, N., Pandey, A., Jayashankar, L. & Mittal, S. K. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol. Ther. 16, 965\u2013971 (2008).","journal-title":"Mol. Ther."},{"key":"1198_CR31","doi-asserted-by":"publisher","first-page":"100372","DOI":"10.1016\/j.xcrm.2021.100372","volume":"2","author":"A Khan","year":"2021","unstructured":"Khan, A. et al. A recombinant bovine adenoviral mucosal vaccine expressing mycobacterial antigen-85B generates robust protection against tuberculosis in mice. Cell Rep. Med. 2, 100372 (2021).","journal-title":"Cell Rep. Med."},{"key":"1198_CR32","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1128\/JVI.02192-06","volume":"81","author":"J Zhu","year":"2007","unstructured":"Zhu, J., Huang, X. & Yang, Y. Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways. J. Virol. 81, 3170\u20133180 (2007).","journal-title":"J. Virol."},{"key":"1198_CR33","doi-asserted-by":"publisher","unstructured":"Sayedahmed, E. E. et al. Development of NP-based universal vaccine for Influenza A viruses. Vaccines 12, https:\/\/doi.org\/10.3390\/vaccines12020157 (2024).","DOI":"10.3390\/vaccines12020157"},{"key":"1198_CR34","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.virol.2009.06.029","volume":"392","author":"X Li","year":"2009","unstructured":"Li, X., Bangari, D. S., Sharma, A. & Mittal, S. K. Bovine adenovirus serotype 3 utilizes sialic acid as a cellular receptor for virus entry. Virology 392, 162\u2013168 (2009).","journal-title":"Virology"},{"key":"1198_CR35","doi-asserted-by":"publisher","unstructured":"Abou-Saleh, H. et al. Neutralizing antibodies against SARS-CoV-2 are higher but decline faster in mRNA vaccinees compared to individuals with natural infection. J. Travel Med. 29, https:\/\/doi.org\/10.1093\/jtm\/taac130 (2022).","DOI":"10.1093\/jtm\/taac130"},{"key":"1198_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39816-4","volume":"14","author":"T Hertz","year":"2023","unstructured":"Hertz, T. et al. Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2. Nat. Commun. 14, 4575 (2023).","journal-title":"Nat. Commun."},{"key":"1198_CR37","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1084\/jem.20092532","volume":"207","author":"PA Darrah","year":"2010","unstructured":"Darrah, P. A. et al. IL-10 production differentially influences the magnitude, quality, and protective capacity of Th1 responses depending on the vaccine platform. J. Exp. Med. 207, 1421\u20131433 (2010).","journal-title":"J. Exp. Med."},{"key":"1198_CR38","doi-asserted-by":"publisher","first-page":"7103","DOI":"10.1128\/jvi.70.10.7103-7107.1996","volume":"70","author":"DP Sharma","year":"1996","unstructured":"Sharma, D. P., Ramsay, A. J., Maguire, D. J., Rolph, M. S. & Ramshaw, I. A. Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J. Virol. 70, 7103\u20137107 (1996).","journal-title":"J. Virol."},{"key":"1198_CR39","first-page":"39","volume":"350","author":"EB Wilson","year":"2011","unstructured":"Wilson, E. B. & Brooks, D. G. The role of IL-10 in regulating immunity to persistent viral infections. Curr. Top. Microbiol. Immunol. 350, 39\u201365 (2011).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"1198_CR40","doi-asserted-by":"publisher","first-page":"27158","DOI":"10.1074\/jbc.M115.682708","volume":"290","author":"SK Mittal","year":"2015","unstructured":"Mittal, S. K., Cho, K. J., Ishido, S. & Roche, P. A. Interleukin 10 (IL-10)-mediated Immunosuppression: march-i induction regulates antigen presentation by macrophages but not dendritic cells. J. Biol. Chem. 290, 27158\u201327167 (2015).","journal-title":"J. Biol. Chem."},{"key":"1198_CR41","doi-asserted-by":"publisher","first-page":"e2183","DOI":"10.1002\/rmv.2183","volume":"31","author":"A Arashkia","year":"2021","unstructured":"Arashkia, A. et al. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: state of the art and future prospects. Rev. Med. Virol. 31, e2183 (2021).","journal-title":"Rev. Med. Virol."},{"key":"1198_CR42","doi-asserted-by":"publisher","first-page":"701501","DOI":"10.3389\/fimmu.2021.701501","volume":"12","author":"D Mart\u00ednez-Flores","year":"2021","unstructured":"Mart\u00ednez-Flores, D. et al. SARS-CoV-2 vaccines based on the spike glycoprotein and implications of new viral variants. Front. Immunol. 12, 701501 (2021).","journal-title":"Front. Immunol."},{"key":"1198_CR43","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/vaccines10111807","volume":"10","author":"J Li","year":"2022","unstructured":"Li, J. et al. Development of bivalent mRNA vaccines against SARS-CoV-2 variants. Vaccines 10, 1807 (2022).","journal-title":"Vaccines"},{"key":"1198_CR44","doi-asserted-by":"publisher","first-page":"117793222110258","DOI":"10.1177\/11779322211025876","volume":"15","author":"R Gorkhali","year":"2021","unstructured":"Gorkhali, R. et al. Structure and function of major SARS-CoV-2 and SARS-CoV proteins. Bioinform. Biol. Insights 15, 11779322211025876 (2021).","journal-title":"Bioinform. Biol. Insights"},{"key":"1198_CR45","doi-asserted-by":"publisher","unstructured":"Bai, Z., Cao, Y., Liu, W. & Li, J. The SARS-CoV-2 nucleocapsid protein and its role in viral structure, biological functions, and a potential target for drug or vaccine mitigation. Viruses 13, https:\/\/doi.org\/10.3390\/v13061115 (2021).","DOI":"10.3390\/v13061115"},{"key":"1198_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.micinf.2020.04.002","volume":"22","author":"B Tilocca","year":"2020","unstructured":"Tilocca, B. et al. Comparative computational analysis of SARS-CoV-2 nucleocapsid protein epitopes in taxonomically related coronaviruses. Microbes Infect. 22, 188\u2013194 (2020).","journal-title":"Microbes Infect."},{"key":"1198_CR47","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/S1672-0229(03)01016-7","volume":"1","author":"Y Hu","year":"2003","unstructured":"Hu, Y. et al. The M protein of SARS-CoV: basic structural and immunological properties. Genom. Proteom. Bioinforma. 1, 118\u2013130 (2003).","journal-title":"Genom. Proteom. Bioinforma."},{"key":"1198_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/vaccines12020157","volume":"12","author":"EE Sayedahmed","year":"2024","unstructured":"Sayedahmed, E. E. et al. Development of NP-based universal vaccine for influenza A viruses. Vaccines 12, 157 (2024).","journal-title":"Vaccines"},{"key":"1198_CR49","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.omtm.2023.06.009","volume":"30","author":"EE Sayedahmed","year":"2023","unstructured":"Sayedahmed, E. E. et al. Impact of an autophagy-inducing peptide on immunogenicity and protection efficacy of an adenovirus-vectored SARS-CoV-2 vaccine. Mol. Ther. Methods Clin. Dev. 30, 194\u2013207 (2023).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1198_CR50","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1182\/blood-2003-12-4302","volume":"104","author":"S Bhattacharyya","year":"2004","unstructured":"Bhattacharyya, S. et al. Immunoregulation of dendritic cells by IL-10 is mediated through suppression of the PI3K\/Akt pathway and of I\u03baB kinase activity. Blood 104, 1100\u20131109 (2004).","journal-title":"Blood"},{"key":"1198_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-11803-y","volume":"7","author":"RE Mitchell","year":"2017","unstructured":"Mitchell, R. E. et al. IL-4 enhances IL-10 production in Th1 cells: implications for Th1 and Th2 regulation. Sci. Rep. 7, 11315 (2017).","journal-title":"Sci. Rep."},{"key":"1198_CR52","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/mi.2010.8","volume":"3","author":"D Jankovic","year":"2010","unstructured":"Jankovic, D., Kugler, D. G. & Sher, A. IL-10 production by CD4+ effector T cells: a mechanism for self-regulation. Mucosal Immunol. 3, 239\u2013246 (2010).","journal-title":"Mucosal Immunol."},{"key":"1198_CR53","doi-asserted-by":"publisher","first-page":"455","DOI":"10.3389\/fimmu.2018.00455","volume":"9","author":"S Sch\u00fclke","year":"2018","unstructured":"Sch\u00fclke, S. Induction of interleukin-10 producing dendritic cells as a tool to suppress allergen-specific T helper 2 responses. Front. Immunol. 9, 455 (2018).","journal-title":"Front. Immunol."},{"key":"1198_CR54","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.3390\/v14122727","volume":"14","author":"W-C Wang","year":"2022","unstructured":"Wang, W.-C., Sayedahmed, E. E. & Mittal, S. K. Significance of preexisting vector immunity and activation of innate responses for adenoviral vector-based therapy. Viruses 14, 2727 (2022).","journal-title":"Viruses"},{"key":"1198_CR55","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.virusres.2010.07.021","volume":"153","author":"A Sharma","year":"2010","unstructured":"Sharma, A., Bangari, D. S., Tandon, M., Hogenesch, H. & Mittal, S. K. Evaluation of innate immunity and vector toxicity following inoculation of bovine, porcine or human adenoviral vectors in a mouse model. Virus Res. 153, 134\u2013142 (2010).","journal-title":"Virus Res."},{"key":"1198_CR56","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.omtm.2018.07.007","volume":"10","author":"EE Sayedahmed","year":"2018","unstructured":"Sayedahmed, E. E. et al. A bovine adenoviral vector-based H5N1 Influenza -vaccine provides enhanced immunogenicity and protection at a significantly low dose. Mol. Ther. Methods Clin. Dev. 10, 210\u2013222 (2018).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"1198_CR57","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMra2206573","volume":"387","author":"DH Barouch","year":"2022","unstructured":"Barouch, D. H. COVID-19 vaccines\u2014immunity, variants, boosters. N. Engl. J. Med. 387, 1011\u20131020 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR58","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1056\/NEJMc2032195","volume":"384","author":"AT Widge","year":"2021","unstructured":"Widge, A. T. et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N. Engl. J. Med. 384, 80\u201382 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR59","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1056\/NEJMc2103916","volume":"384","author":"N Doria-Rose","year":"2021","unstructured":"Doria-Rose, N. et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19. N. Engl. J. Med. 384, 2259\u20132261 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR60","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1126\/science.abj4176","volume":"373","author":"A Pegu","year":"2021","unstructured":"Pegu, A. et al. Durability of mRNA-1273 vaccine\u2013induced antibodies against SARS-CoV-2 variants. Science 373, 1372\u20131377 (2021).","journal-title":"Science"},{"key":"1198_CR61","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1001\/jama.2021.3645","volume":"325","author":"KE Stephenson","year":"2021","unstructured":"Stephenson, K. E. et al. Immunogenicity of the Ad26. COV2. S Vaccine for COVID-19. JAMA 325, 1535\u20131544 (2021).","journal-title":"JAMA"},{"key":"1198_CR62","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1056\/NEJMc2108829","volume":"385","author":"DH Barouch","year":"2021","unstructured":"Barouch, D. H. et al. Durable humoral and cellular immune responses 8 months after Ad26.COV2.S vaccination. N. Engl. J. Med. 385, 951\u2013953 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR63","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1056\/NEJMc2115596","volume":"385","author":"AY Collier","year":"2021","unstructured":"Collier, A. Y. et al. Differential kinetics of immune responses elicited by COVID-19 vaccines. N. Engl. J. Med. 385, 2010\u20132012 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1198_CR64","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3201\/eid2801.212220","volume":"28","author":"R Gharpure","year":"2022","unstructured":"Gharpure, R. et al. Multistate outbreak of SARS-CoV-2 infections, including vaccine breakthrough infections, associated with large public gatherings, United States. Emerg. Infect. Dis. 28, 35\u201343 (2022).","journal-title":"Emerg. Infect. Dis."},{"key":"1198_CR65","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1099\/0022-1317-36-1-59","volume":"36","author":"FL Graham","year":"1977","unstructured":"Graham, F. L., Smiley, J., Russell, W. C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59\u201374 (1977).","journal-title":"J. Gen. Virol."},{"key":"1198_CR66","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/BF02369439","volume":"22","author":"L Chen","year":"1996","unstructured":"Chen, L., Anton, M. & Graham, F. L. Production and characterization of human 293 cell lines expressing the site-specific recombinase Cre. Somat. Cell Mol. Genet. 22, 477\u2013488 (1996).","journal-title":"Somat. Cell Mol. Genet."},{"key":"1198_CR67","doi-asserted-by":"publisher","first-page":"5882","DOI":"10.1128\/JVI.76.12.5882-5892.2002","volume":"76","author":"AL van Olphen","year":"2002","unstructured":"van Olphen, A. L. & Mittal, S. K. Development and characterization of bovine x human hybrid cell lines that efficiently support the replication of both wild-type bovine and human adenoviruses and those with E1 deleted. J. Virol. 76, 5882\u20135892 (2002).","journal-title":"J. Virol."},{"key":"1198_CR68","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41594-020-0479-4","volume":"27","author":"R Henderson","year":"2020","unstructured":"Henderson, R. et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat. Struct. Mol. Biol. 27, 925\u2013933 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1198_CR69","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-1-4939-9065-8_9","volume":"1937","author":"EE Sayedahmed","year":"2019","unstructured":"Sayedahmed, E. E., Kumari, R. & Mittal, S. K. Current use of adenovirus vectors and their production methods. Methods Mol. Biol. 1937, 155\u2013175 (2019).","journal-title":"Methods Mol. Biol."},{"key":"1198_CR70","doi-asserted-by":"publisher","first-page":"e33428","DOI":"10.1371\/journal.pone.0033428","volume":"7","author":"A Pandey","year":"2012","unstructured":"Pandey, A. et al. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS ONE 7, e33428 (2012).","journal-title":"PLoS ONE"},{"key":"1198_CR71","doi-asserted-by":"publisher","first-page":"e62496","DOI":"10.1371\/journal.pone.0062496","volume":"8","author":"SV Vemula","year":"2013","unstructured":"Vemula, S. V. et al. Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness. PLoS ONE 8, e62496 (2013).","journal-title":"PLoS ONE"},{"key":"1198_CR72","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1099\/0022-1317-78-11-2933","volume":"78","author":"Z Papp","year":"1997","unstructured":"Papp, Z., Middleton, D. M., Mittal, S. K., Babiuk, L. A. & Baca-Estrada, M. E. Mucosal immunization with recombinant adenoviruses: induction of immunity and protection of cotton rats against respiratory bovine herpesvirus type 1 infection. J. Gen. Virol. 78, 2933\u20132943 (1997).","journal-title":"J. Gen. Virol."},{"key":"1198_CR73","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1006\/viro.1995.1553","volume":"213","author":"SK Mittal","year":"1995","unstructured":"Mittal, S. K., Middleton, D. M., Tikoo, S. K. & Babiuk, L. A. Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). Virology 213, 131\u2013139 (1995).","journal-title":"Virology"},{"key":"1198_CR74","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0264-410X(00)00170-5","volume":"19","author":"SK Mittal","year":"2000","unstructured":"Mittal, S. K. et al. Immunization with DNA, adenovirus or both in biodegradable alginate microspheres: effect of route of inoculation on immune response. Vaccine 19, 253\u2013263 (2000).","journal-title":"Vaccine"},{"key":"1198_CR75","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(06)68076-8","volume":"367","author":"MA Hoelscher","year":"2006","unstructured":"Hoelscher, M. A. et al. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367, 475\u2013481 (2006).","journal-title":"Lancet"},{"key":"1198_CR76","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.1016\/j.vaccine.2020.10.039","volume":"38","author":"D Muraoka","year":"2020","unstructured":"Muraoka, D. et al. Identification of a dominant CD8\u2009+\u2009CTL epitope in the SARS-associated coronavirus 2 spike protein. Vaccine 38, 7697\u20137701 (2020).","journal-title":"Vaccine"},{"key":"1198_CR77","doi-asserted-by":"publisher","first-page":"114215","DOI":"10.1016\/j.jviromet.2021.114215","volume":"295","author":"JR Brown","year":"2021","unstructured":"Brown, J. R. et al. Comparison of SARS-CoV-2 N gene real-time RT-PCR targets and commercially available mastermixes. J. Virol. Methods 295, 114215 (2021).","journal-title":"J. Virol. Methods"}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01198-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01198-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01198-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T17:44:01Z","timestamp":1757267041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01198-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,19]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01198-7","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,19]]},"assertion":[{"value":"2 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"159"}}